삼성바이오로직스, 미국 주요 제약사와 22억 달러 규모 CDMO 계약 체결
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
Samsung Biologics secured its largest ever $2.2 billion multi-year CDMO contract with a major US pharmaceutical company for biologics manufacturing at its Songdo campus.
삼성바이오로직스는 익명의 미국 주요 제약사와 22억 달러 규모의 CDMO(위탁개발생산) 계약을 체결했습니다. 이번 다년 계약은 삼성바이오로직스 송도 캠퍼스에서 바이오의약품 생산을 담당하며, 4공장 완공 시 총 78만 4천 리터의 생산 능력을 갖추게 됩니다. 이는 창사 이래 단일 CDMO 계약으로는 최대 규모입니다.
Samsung Biologics' mega-deal confirms South Korea's emergence as the world's premier biologics CDMO hub, rivaling traditional manufacturing centers in the US and Europe.
Where this signal fits in the broader landscape.
No recent signals tracked yet.
https://koreajoongangdaily.joins.com/news/2025-05-26/business/industry/Samsung-Biologics-manufacturing-deals-exceed-22-billion-this-year/2315474
Read Full SourceGet curated intelligence delivered to your inbox. No spam, unsubscribe anytime.
Sign in to save notes on signals.
로그인